EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide

John J Lee, Haval Norman, Jamie E Ziggas, Javier Bolaños-Meade, Timothy J Porter

Transplantation and Cellular Therapy · 2025

DOI: 10.1016/j.jtct.2025.02.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2025. Verfasst von John J Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland. Hauptthemen laut MEDLINE: Graft vs Host Disease, Cyclophosphamide, Immunosuppressive Agents, Bone Marrow Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-transplantation cyclophosphamide (PTCy) is standard graft-versus-host disease (GVHD) prophylaxis for allogeneic blood or marrow transplantation (alloBMT), although optimal therapeutic levels of immunosuppression (IS) therapy combined with PTCy remain contested. Previously, with tacrolimus and methotrexate GVHD prophylaxis, week 1 tacrolimus levels >12 ng/mL were associated with a decreased incidence of grade 2 to 4 acute GVHD (aGVHD). We evaluated if associations between aGVHD and early IS levels were observed amongst patients receiving PTCy. This retrospective single-center study consisted of 349 patients who received PTCy and mycophenolate mofetil, with either tacrolimus (n = 185) or sirolimus (n = 164) from September 1, 2017, to September 30, 2019. The median age of patients receiving tacrolimus and sirolimus were 58 and 54 years, respectively. The primary diagnosed diseases for both cohorts were acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and lymphoma. While most patients receiving tacrolimus were bone marrow graft sourced (78.4%), the majority of patients receiving sirolimus were peripheral blood sourced (80.5%). All patients were transplanted with FluCyTBI as the conditioning regimen. The primary outcome was grade 2 to 4 aGVHD incidence at 150 days post alloBMT between weekly IS levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseCyclophosphamideImmunosuppressive AgentsBone Marrow TransplantationImmunosuppression TherapyHumansMiddle AgedMaleFemaleRetrospective StudiesAdultTransplantation, HomologousAgedTacrolimus

Stichwörter der Autor:innen

Graft-versus-host-diseasePost-transplant cyclophosphamideSirolimusTacrolimus

Substanzen

CyclophosphamideImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland.
  • Division of Hematological Malignancies and Bone Marrow Transplantation, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland. Electronic address: fbolano2@jhmi.edu.

Förderung

  • National Cancer Center

Zitieren

APA

Lee, J. J., Norman, H., Ziggas, J. E., Bolaños-Meade, J., & Porter, T. J. (2025). Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2025.02.024

Vancouver

Lee JJ, Norman H, Ziggas JE, Bolaños-Meade J, Porter TJ. Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 2025. doi:10.1016/j.jtct.2025.02.024

BibTeX
@article{Lee2025,
  author = {Lee, John J and Norman, Haval and Ziggas, Jamie E and Bolaños-Meade, Javier and Porter, Timothy J},
  title = {Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide},
  journal = {Transplantation and Cellular Therapy},
  year = {2025},
  doi = {10.1016/j.jtct.2025.02.024}
}
Kostenlos starten →